No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240621C115000
- 0.10
- 0.000.00%
15min DelayTrading Jun 5 14:04 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume33 Open Interest115.00Strike Price0.00Turnover31.22%IV8.72%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0487Delta0.0201Gamma1058.65Leverage Ratio-0.0291Theta0.0012Rho51.58Eff Leverage0.0162Vega
Intraday
- 5D
- 1D
News
Express News | World Health Organization Chief: At This Time, Who Continues To Assess Risk To Public Health From H5n1 As Low
Is Novartis AG (NYSE:NVS) Investors' Favorite International Dividend Stock?
Top Gap Ups and Downs on Friday: INFY, SHW, WIT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy
Abu Dhabi's Department of Health and Novartis (NOVN.SW) unit Novartis Middle East FZE signed a memorandum of understanding for a partnership aimed at advancing genomics research in oncology and other
Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics Research in Oncology and Beyond
ABU DHABI, UAE, June 6, 2024 /PRNewswire/ -- At BIO 2024 International Convention, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorand
Why Novartis (NVS) Is a Top Value Stock for the Long-Term
Comments
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
1
Read more